Learn about analytical test solutions for Type II Diabetes that enable the creation of high quality laboratory data sets
Join ICON’s expert Dr. Andrew Roche, PhD as he speaks about overcoming challenges when developing Diabetes trials. Addressing these challenges via use of high quality tools is critical to successful completion of a clinical trial.
It is the belief of ICON Central Laboratories that these considered solutions will provide high quality options that will increase the opportunity for success for those undertaking the challenge posed by drug development.
Key insights include:
- The creation of high quality laboratory data sets as a means of enabling an accurate and efficient assessment of the test compound.
- Understanding the value of global laboratory harmonisation when performing global clinical trial.
- Accurately defining clinical status via laboratory endpoints.
Dr. Martin Benson, PhD
Senior Director and Global Lead, Cardiometabolic Drug Development Services, ICON
Dr. Benson is a highly knowledgeable cardiometabolic pharmacologist with over 36 years of experience. Dr. Benson has experience working internationally in preclinical research and early clinical development in blue-chip pharmaceutical companies. He gained his PhD in Pharmacology/Biochemistry at the Royal Veterinary College, University of London.
Dr. Andrew Roche, PhD
Scientific Director, Global Validation, Scientific Affairs
Andrew, a PhD with in depth knowledge of the intricacies of analytical methods and their applications within clinical trials, oversees the Scientific Affairs and Global Validations functions of ICON Central Laboratories.
Andrew has over 15 years’ experience in the clinical trial industry. He began his career within the infectious disease arena of biotech where he successfully led projects designed to identify and validate large molecule drug targets within pathogenic microorganisms. Andrew then moved into the field of biomarkers and led projects that created marketed immunoassay products for the detection of novel biomarkers of organ toxicity. Prior to joining ICON Andrew co-founded a bioanalytical CRO dedicated to the development, validation and utilization of customised methods for the quantification of large molecule drugs, anti-drug antibodies and biomarkers.
Andrew holds a B.A. Mod, and Ph.D. in Medical Microbiology from Trinity College Dublin and has authored several scientific publications. In his current role as Scientific Director he focuses on the intricacies of analytical methods and their applications within clinical trials with the goal of facilitating the creation of an accurate and precise analytical data set thereby facilitating an accurate clinical assessment of analytical data.
This program is intended for senior professionals from biopharmaceutical companies working within diabetes clinical research.